<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00415090</url>
  </required_header>
  <id_info>
    <org_study_id>TRIMUNE</org_study_id>
    <nct_id>NCT00415090</nct_id>
  </id_info>
  <brief_title>Study to Evaluate the Replacement of Reverse Transcriptase Nucleoside/Nucleotide Inhibitors by Nevirapine in Patients on Triple Treatment With Analogues Only</brief_title>
  <official_title>Substitution by Nevirapine in HIV-1 Infected Patients on Triple Treatment of Reverse Transcriptase Nucleoside/Nucleotide Inhibitors</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Hospital de Calella</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Hospital de Calella</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to evaluate the proportion of patients with viral load of HIV-1
      &lt; 50 copies after 48 weeks of follow-up after randomization to change or not to nevirapine.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      RTNI (reverse transcriptase nucleoside inhibitors) are a regular part of most antiretroviral
      combinations. The presence of a smaller or greater degree of cross resistance among all RTNI
      is increasingly better described and acknowledged, whereby the number of salvage regimens
      that may be built following the appearance of this resistance to these drugs is by no means
      unlimited.

      This proactive treatment change in patients on RTNI-based regimens while the viral load is
      still suppressed would avoid the selective replication period under antiviral pressure
      following the failure of the regimen in which resistance-associated mutations accumulate.
      This therapeutic approach has demonstrated its effectiveness in clinical practice, albeit not
      in this scenario.

      If we wait until the viral load is detectable there is sufficient evidence that resistance to
      RTNI will appear and that this resistance will compromise future salvage options.

      To intensify with this proactive approach these combinations based on N/NNRTI (nucleotide
      analog), the NNRTI are an optimal alternative.There is vast experience with NVP in
      simplification/maintenance trials. In direct comparative simplification studies in patients
      with virological response, the response rates with NVP or EFV have shown no differences. With
      a relative risk (RR) of virological failure of 0.54 with regard to the continuation of PI
      (protease inhibitors), NVP is one of the best simplification treatment options in
      HIV-1-infected patients.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>August 2004</start_date>
  <completion_date type="Actual">July 2006</completion_date>
  <primary_completion_date type="Actual">July 2006</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Proportion of patients with plasma viral load below 50 copies/mL .</measure>
    <time_frame>after 48 weeks of follow-up</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Time to the appearance of viral load &gt;50 copies/mL in both branches (two consecutive determinations with 4-week separation between both).</measure>
    <time_frame>During the 48 weeks of follow-up.</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Evolution of the CD4 lymphocyte count at 48 weeks.</measure>
    <time_frame>during 48 weeks of follow-up</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Pattern of mutations associated with resistance in patients presenting virological failure.</measure>
    <time_frame>When there is a virological failure</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Incidence of adverse clinical effects and laboratory alterations, giving rise or not to the withdrawal of the investigational treatment.</measure>
    <time_frame>during the 48 weeks of follow-up</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Incidence of AIDS-defining events (CDC C events, 1993).</measure>
    <time_frame>during the 48 weeks of follow-up</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Mortality by any cause.</measure>
    <time_frame>during the 48 weeks of follow-up</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">28</enrollment>
  <condition>HIV Infections</condition>
  <arm_group>
    <arm_group_label>1</arm_group_label>
    <arm_group_type>No Intervention</arm_group_type>
    <description>Follow with same ARV treatment</description>
  </arm_group>
  <arm_group>
    <arm_group_label>2</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Switch one of ARV drugs to Nevirapine</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Nevirapine</intervention_name>
    <description>Switch one of ARV drugs to Nevirapine</description>
    <arm_group_label>2</arm_group_label>
    <other_name>Switch one of ARV drugs to Nevirapine</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Patients on triple treatment with 3 nucleoside analogues or transcriptase nucleotide
             inhibitors in virological suppression.

          -  Age &gt;= 18 years.

          -  Confirmed diagnosis of HIV-1 infection.

          -  Viral load &lt; 50 copies/ml over the previous six months, including at least two
             consecutive determinations.

          -  Value of ALT transaminase £ 2.5 times the normal value of the laboratory of each
             centre.

          -  Acceptance and signature of the informed consent form.

        Exclusion Criteria:

          -  Pregnant women or those who intend to become pregnant in the study period.

          -  Having had an active infection in the previous month.

          -  Previous exposure to any reverse transcriptase non-nucleoside inhibitor (nevirapine,
             efavirenz or delavirdine).

          -  Simultaneous treatment with methadone.

          -  Patients with serious hepatic dysfunction
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Josep Mª Llibre, MD,PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Hospital Sant Jaume de Calella</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Hospital.Universitari Germans Trias i Pujol</name>
      <address>
        <city>Badalona</city>
        <state>Barcelona</state>
        <zip>08916</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital General de Granollers</name>
      <address>
        <city>Granollers</city>
        <state>Barcelona</state>
        <zip>08400</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Centre Penitenciari Quatre Camins</name>
      <address>
        <city>Granollers</city>
        <state>Barcelona</state>
        <zip>08430</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital de Bellvitge</name>
      <address>
        <city>Hospitalet de Llobregat</city>
        <state>Barcelona</state>
        <zip>08907</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Mutua de Terrassa</name>
      <address>
        <city>Terrassa</city>
        <state>Barcelona</state>
        <zip>08221</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital La Candelaria</name>
      <address>
        <city>Tenerife</city>
        <state>Canarias</state>
        <zip>38010</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital Universitari Sant Joan de Reus</name>
      <address>
        <city>Reus</city>
        <state>Tarragona</state>
        <zip>43201</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Centre Penitenciari Brians</name>
      <address>
        <city>Barcelona</city>
        <zip>08009</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hopsital de Sant Pau</name>
      <address>
        <city>Barcelona</city>
        <zip>08025</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital Vall d'Hebron</name>
      <address>
        <city>Barcelona</city>
        <zip>08035</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital Clínic i Provincial de Barcelona</name>
      <address>
        <city>Barcelona</city>
        <zip>08036</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital Sant Jaume de Calella</name>
      <address>
        <city>Barcelona</city>
        <zip>08370</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Centre Penitenciari Homes</name>
      <address>
        <city>Barcelona</city>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital Clínico San Carlos de Madrid</name>
      <address>
        <city>Madrid</city>
        <zip>28040</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital de Tortosa</name>
      <address>
        <city>Tortosa</city>
        <zip>43500</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital La Fe de Valencia</name>
      <address>
        <city>Valencia</city>
        <zip>46009</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital Miguel Servet</name>
      <address>
        <city>Zaragoza</city>
        <zip>50009</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Spain</country>
  </location_countries>
  <verification_date>October 2008</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>December 19, 2006</study_first_submitted>
  <study_first_submitted_qc>December 21, 2006</study_first_submitted_qc>
  <study_first_posted type="Estimate">December 22, 2006</study_first_posted>
  <last_update_submitted>October 30, 2008</last_update_submitted>
  <last_update_submitted_qc>October 30, 2008</last_update_submitted_qc>
  <last_update_posted type="Estimate">October 31, 2008</last_update_posted>
  <responsible_party>
    <name_title>Hospital San Jaime de Calella</name_title>
    <organization>Hospital San Jaime de Calella</organization>
  </responsible_party>
  <keyword>Nevirapine</keyword>
  <keyword>Antiretroviral treatment</keyword>
  <keyword>Triple nucleoside therapy</keyword>
  <keyword>HIV</keyword>
  <keyword>Treatment Experienced</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>HIV Infections</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Nevirapine</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

